报告包：Claudin 18.2 标靶免疫治疗

Report Package: Claudin 18.2-Targeted Immunotherapeutics

出版日期: 2024年04月30日 | 出版商:

La Merie Publishing | 英文 314 Pages | 订单完成后即时交付

价格

简介目录

Claudin18.2是一种高度特异性的细胞表面分子，不仅在原发性胃癌中异常表达，而且在胰腺癌和食道癌等其他实体癌中也经常异常表达。 Claudin18.2 作为癌症标靶引起了人们的极大兴趣，用于开发针对 Claudin18.2 本身的免疫疗法候选药物。 Claudin18.2 不仅有望成为一种有效的治疗方法，还能够应用多种药物疗法来产生候选化合物。在日本批准第一个针对 Claudin18.2 的免疫疗法后，至少有 44 个候选药物处于临床阶段，10 个候选药物处于临床前或 IND/CTA 开发阶段。

本报告包□□从行业角度（2023年（截至8月））详细分析了针对Claudin18.2的免疫疗法的行业格局、利益相关者、药物模式、管道、商机等。此外，我们截至 2024 年 4 月的竞争分析考察了 Claudin18.2 标靶免疫疗法候选药物的最新竞争领域。

Claudin18.2 (CLDN18.2) 标靶裸单株抗体
CLDN18.2标靶抗体药物偶联物
CLDN18.2靶向CAR-T细胞/NK细胞
CLDN18.2标靶T细胞募集双特异性抗体
CLDN18.2/PD-L1标靶双特异性抗体
CLDN18.2□4-1BB (CD137) 标靶双特异性抗体
针对 CLDN18.2/CD47/SIRP-α 或 CD8 的双特异性抗体

简介目录

Product Code: LMFR0040

Claudin18.2 is a highly specific cell surface molecule that is often abnormally expressed in primary gastric cancer as well as in other solid tumors such as pancreatic and esophageal cancers. Claudin 18.2 has gained considerable interest as a cancer target for development of claudin 18.2-targeted immunotherapy candidates. Apart from providing promise as an effective therapy, it also allows the application of a wide variety of drug modalities to generate development candidates. After approval in Japan of the first immunotherapy against claudin 18.2, the pipeline is packed with at least 44 candidates in the clinical stage and ten in the non-clinical or IND/CTA development stage.

This report package includes a full report of August 2023 analyzing in depth the landscape of claudin 18.2-targeted immunotherapy regarding stakeholders, drug modalities, pipeline and business opportunities from an industry perspective. The competitor analysis of April 2024 updates the competitive field of CLDN18.2-targeted immunotherapy candidates.